- Issuer ticker
-
QNCX
- Reported as of
-
18 Jun 2025
- Net transaction value
-
+$50,000
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
23 Jun 2025, 08:48:00 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Brendan Hannah
Key filing fact
Brendan Hannah filed Form 4 for Quince Therapeutics, Inc. (QNCX) on 23 Jun 2025.
Key facts
- This page summarizes Brendan Hannah's Form 4 filing for Quince Therapeutics, Inc. (QNCX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Jun 2025, 08:48.
Change
- Previous filing in this sequence was filed on 11 Feb 2025.
- Current net transaction value: +$50,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001929422
Primary reporting owner
Hannah Brendan
- Relationship
-
CBO, COO & CCO
- Address
- C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
- Signature
- /s/ Brendan Hannah
- Signature date
- 20 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QNCX
transaction
Common Shares
Award
- Transaction value
- $45,283
- Shares
- +37,736
- Change %
- +13%
- Price
-
$1.20
- Shares after
- 334,276
- Date
- 18 Jun 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QNCX
transaction
Derivative
Warrants
Award
- Transaction value
- $4,717
- Shares
- +37,736
- Change %
- Price
-
$0.1250
- Shares after
- 37,736
- Date
- 18 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 37,736
- Exercise price
- $1.20
* marks a reported price that did not pass the local price check.